Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIFIREINS: Rituximab at first episode of minimal change nephrotic syndrome in adults
2024-516102-36-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of rituximab in nephrosis (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Incidence of MCNS relapse at 12 months. Planned start Jul 2020; status: authorised.
02
Drugs
rituximab
03
Conditions
nephrosis
Beyond the preview
Go deeper on 2024-516102-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516102-36-00.